These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 23625556)

  • 1. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
    Gonçalves N; Simões AT; Cunha RA; de Almeida LP
    Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
    Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
    Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products.
    Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P
    Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
    Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
    PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine alleviates progressive motor deficits in a transgenic mouse model of spinocerebellar ataxia.
    Gonçalves N; Simões AT; Prediger RD; Hirai H; Cunha RA; Pereira de Almeida L
    Ann Neurol; 2017 Mar; 81(3):407-418. PubMed ID: 28032667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
    Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
    Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
    Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease.
    Simões AT; Gonçalves N; Nobre RJ; Duarte CB; Pereira de Almeida L
    Hum Mol Genet; 2014 Sep; 23(18):4932-44. PubMed ID: 24817574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
    Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
    Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of Onuf's nucleus in Machado-Joseph disease: a morphometric and immunohistochemical study.
    Shimizu H; Yamada M; Toyoshima Y; Ikeuchi T; Onodera O; Takahashi H
    Acta Neuropathol; 2010 Oct; 120(4):439-48. PubMed ID: 20503052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration.
    Goti D; Katzen SM; Mez J; Kurtis N; Kiluk J; Ben-Haïem L; Jenkins NA; Copeland NG; Kakizuka A; Sharp AH; Ross CA; Mouton PR; Colomer V
    J Neurosci; 2004 Nov; 24(45):10266-79. PubMed ID: 15537899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Conceição M; Déglon N; de Almeida LP
    Cerebellum; 2013 Aug; 12(4):441-55. PubMed ID: 23242710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compromised mitochondrial complex II in models of Machado-Joseph disease.
    Laço MN; Oliveira CR; Paulson HL; Rego AC
    Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
    Tsai HF; Tsai HJ; Hsieh M
    Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
    Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP
    Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain.
    Paulson HL; Das SS; Crino PB; Perez MK; Patel SC; Gotsdiner D; Fischbeck KH; Pittman RN
    Ann Neurol; 1997 Apr; 41(4):453-62. PubMed ID: 9124802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease.
    Duarte-Neves J; Gonçalves N; Cunha-Santos J; Simões AT; den Dunnen WF; Hirai H; Kügler S; Cavadas C; Pereira de Almeida L
    Hum Mol Genet; 2015 Oct; 24(19):5451-63. PubMed ID: 26220979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.